Business
10x Genomics Announces Patent Litigation Settlement Agreement with Bruker
PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has
About this update from 10x Genomics, Inc.
[{"type":"text","content":"PLEASANTON, Calif., May 14, 2025 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG), a leader in single cell and spatial biology, today announced that it has reached a settlement agreement with Bruker Corporation, successfully resolving all outstanding worldwide patent litigation and disputes between the two companies. As part of the settlement, 10x expects that Bruker will pay $68 million in equal quarterly installments between the third quarter of 2025 and the second quarter of 2026, as well as ongoing royalties on sales of its spatial biology products through the life of the licensed patents. \n\n \n \n \n \n \n \n\n \n\"At 10x, we've always believed that bold, original science must be protected, not just for the benefit of a company, but for the entire scientific ecosystem,\" said Serge Saxonov, CEO of 10x Genomics. \"It is our responsibility to defend our intellectual property to fuel innovations that will advance science and human health. We are very happy with the outcome and its validation of our strategy. It reinforces our deep commitment to innovation, bringing great products to market and supporting our customers every step of the way.\"\nEric Whitaker, Chief Legal Officer added, \"This settlement really demonstrates the value of 10x's broad intellectual property portfolio and the fundamental importance of those inventions for spatial biology. We're pleased to conclude these matters on strong terms that support our mission and allow us to continue to invest in future breakthroughs.\"\nThe settlement includes global patent cross-licenses and a complete withdrawal of all legal proceedings, including those in the United States, Germany and before the European Unified Patent Court.\nAbout 10x Genomics\n10x Genomics is a life science technology company building products to accelerate the mastery of biology and advance human health. Our integrated solutions include instruments, consumables and software for single cell and spatial biology, which help academic and translational researchers and biopharmaceutical companies understand biological systems at a resolution and scale that matches the complexity of biology. Our products are behind breakthroughs in oncology, immunology, neuroscience and more, fueling powerful discoveries that are transforming the world's understanding of health and disease. To learn more, visit 10xgenomi...